Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
A number of other equities research analysts have also recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Wednesday, September 2nd. Stifel Nicolaus assumed coverage on shares of Whitehawk Therapeutics in a report on Wednesday, September 30th. They issued a “buy” rating and a $9.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.33.
View Our Latest Report on WHWK
Whitehawk Therapeutics Price Performance
Shares of Whitehawk Therapeutics stock opened at $3.06 on Friday. Whitehawk Therapeutics has a 52 week low of $1.97 and a 52 week high of $5.49. The business’s fifty day simple moving average is $3.53 and its 200-day simple moving average is $3.84. The firm has a market cap of $180.57 million, a PE ratio of -2.81 and a beta of 0.99.
Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. As a group, equities analysts expect that Whitehawk Therapeutics will post -1.00 earnings per share for the current year.
Hedge Funds Weigh In On Whitehawk Therapeutics
Several hedge funds have recently bought and sold shares of WHWK. Two Sigma Securities LLC purchased a new stake in Whitehawk Therapeutics during the second quarter worth about $46,000. OMERS ADMINISTRATION Corp purchased a new stake in Whitehawk Therapeutics during the 1st quarter worth approximately $40,000. Deutsche Bank AG purchased a new stake in Whitehawk Therapeutics during the 2nd quarter worth approximately $145,000. Bank of America Corp DE acquired a new stake in Whitehawk Therapeutics during the 2nd quarter worth approximately $159,000. Finally, Seven Fleet Capital Management LP acquired a new stake in Whitehawk Therapeutics during the 1st quarter worth approximately $187,000. Institutional investors and hedge funds own 52.08% of the company’s stock.
About Whitehawk Therapeutics
Whitehawk Therapeutics is a biopharmaceutical company focused on developing treatments for cancer. Its work centers on oncology drug research and development. Publicly available information provides limited detail about the company’s specific products, development programs, operating geographies, or leadership.
Recommended Stories
- Five stocks we like better than Whitehawk Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
